| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOA1 |
| Uniprot No | P02647 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-267aa |
| 氨基酸序列 | MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOA1重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*Recombinant Apolipoprotein A-I Milano Reduces Atherosclerotic Plaque in Humans*
**作者**：Nissen, S.E. et al.
**摘要**：该研究报道了重组apoA-I Milano(一种APOA1天然突变体)的临床效果。通过静脉注射，显著减少冠心病患者的动脉粥样硬化斑块体积，验证了重组APOA1在心血管疾病治疗中的潜力。
---
2. **文献名称**：*Expression and Purification of Recombinant Human Apolipoprotein A-I in Escherichia coli*
**作者**：Srinivas, R.V. et al.
**摘要**：研究优化了在大肠杆菌中高效表达和纯化重组人APOA1的流程，验证了其结构与天然蛋白的一致性，为大规模生产功能性APOA1提供了技术基础。
---
3. **文献名称**：*Reconstituted HDL Containing Recombinant APOA1 Promotes Cholesterol Efflux and Reduces Inflammation in Mice*
**作者**：Ryan, R.O. et al.
**摘要**：利用重组APOA1与磷脂组装成合成HDL纳米颗粒，实验证明其可促进巨噬细胞胆固醇外流，并在小鼠模型中缓解炎症反应，为动脉粥样硬化治疗提供了新策略。
---
**备注**：若需更近期研究(如CRISPR优化表达或新型递送系统)，建议通过PubMed检索关键词“recombinant APOA1 2020-2023”获取最新进展。
Apolipoprotein A1 (APOA1) is a key structural and functional component of high-density lipoprotein (HDL), often referred to as "good cholesterol." Synthesized primarily in the liver and intestine, APOA1 plays a central role in reverse cholesterol transport (RCT), a process that removes excess cholesterol from peripheral tissues and transports it to the liver for excretion. This 28-kDa protein facilitates HDL assembly, stabilizes its structure, and mediates interactions with cellular receptors and enzymes, such as ATP-binding cassette transporter A1 (ABCA1) and lecithin-cholesterol acyltransferase (LCAT), critical for cholesterol efflux and esterification.
Recombinant APOA1 (rAPOA1) is produced using genetic engineering techniques, typically expressed in bacterial (e.g., E. coli) or mammalian cell systems. Its production enables large-scale study and therapeutic applications. Structurally, rAPOA1 retains the amphipathic α-helical domains of native APOA1. allowing lipid binding and HDL-like particle formation. Modifications, such as truncations or fusion tags, are often introduced to enhance stability, solubility, or purification efficiency.
Research on rAPOA1 has focused on its potential to treat cardiovascular diseases (CVD), particularly atherosclerosis. Studies highlight its ability to promote cholesterol efflux, reduce inflammation, and improve endothelial function. Clinical trials using APOA1 variants (e.g., APOA1 Milano) demonstrated plaque regression in coronary arteries, though broader therapeutic applications remain under investigation. Beyond therapeutics, rAPOA1 serves as a tool to study lipid metabolism, protein-lipid interactions, and HDL functionality. Challenges include optimizing production yields, ensuring biological activity post-purification, and addressing immunogenicity in clinical settings. Ongoing advances in protein engineering and delivery systems aim to enhance its efficacy for CVD and related metabolic disorders.
×
